Mizuho Markets Americas LLC Increases Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Mizuho Markets Americas LLC raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,994 shares of the specialty pharmaceutical company’s stock after purchasing an additional 21,416 shares during the period. Mizuho Markets Americas LLC’s holdings in ANI Pharmaceuticals were worth $15,945,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ANIP. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. lifted its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares during the period. Divisadero Street Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Rubric Capital Management LP lifted its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the period. Finally, UBS Group AG lifted its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares in the company, valued at approximately $2,901,264.30. This represents a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher Mutz sold 3,162 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $71.64, for a total value of $226,525.68. Following the completion of the transaction, the insider owned 91,309 shares of the company’s stock, valued at $6,541,376.76. The trade was a 3.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 91,427 shares of company stock valued at $7,089,066 in the last three months. Insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ANIP shares. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $107.33.

ANI Pharmaceuticals Trading Down 0.1%

NASDAQ:ANIP opened at $82.72 on Friday. The stock has a fifty day moving average price of $77.90 and a two-hundred day moving average price of $80.11. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 20.94 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals’s revenue was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.